News

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute…

2 years ago

Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to…

2 years ago

PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a…

2 years ago

New Study Reveals Effective Treatment for Children Suffering From Persistent Post-Concussion Syndrome

Study shows that hyperbaric oxygen therapy significantly improves symptoms, including memory, emotional and behavioral, and heals brain structure in cortical…

2 years ago

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader…

2 years ago

Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…

2 years ago

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval

FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company…

2 years ago

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…

2 years ago

SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants

SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a…

2 years ago

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

Understanding Hunger & Bardet-Biedl Syndrome (BBS): Gabe’s Story Developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation-- Book developed in…

2 years ago